These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12848158)

  • 1. [Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?].
    Walter MA; Müller B; Müller-Brand J
    Nuklearmedizin; 2003 Jun; 42(3):N29; author reply N29. PubMed ID: 12848158
    [No Abstract]   [Full Text] [Related]  

  • 2. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
    Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
    Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
    Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
    Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
    Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW
    J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
    Eschmann SM; Thelen MH; Dittmann H; Bares R
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radioiodine (I-131) treatment of Graves' disease (author's transl)].
    Rösler H; Kinser J
    Ther Umsch; 1973 Oct; 30(10):717-25. PubMed ID: 4800360
    [No Abstract]   [Full Text] [Related]  

  • 7. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Radioiodine therapy for women with Graves' disease and the risk of foetal hypothyroidism if they are later found to be pregnant].
    Prinsen AK; Jansen J; Bakker WH; Wildschut HI
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2845-8. PubMed ID: 17319213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
    Salvatore D; Fenzi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
    Baczyk M; Junik R; Ziemnicka K; Sowiński J
    Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The outcome of treatment with adjusted dose of 131I to thyroid weight for Graves' disease by estimation of effective half life using a single radioiodine uptake measurement].
    Gomi Y; Watanabe M; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Ito K; Suzuki S
    Kaku Igaku; 2000 Mar; 37(2):109-14. PubMed ID: 10783569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Airway complication occurring during radioiodine treatment for Graves' disease.
    Kinuya S; Yoneyama T; Michigishi T
    Ann Nucl Med; 2007 Aug; 21(6):367-9. PubMed ID: 17705018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Deterioration of endocrine ophthalmology after radioiodine therapy in Graves' disease?].
    Weigand A; Hinzpeter B; Schicha H
    Nuklearmedizin; 1998; 37(7):234-8. PubMed ID: 9830613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ambulatory treatment of hyperthyroidism with radioiodine].
    Konrády A
    Orv Hetil; 2000 Apr; 141(17):938-9; author reply 939-41. PubMed ID: 10827475
    [No Abstract]   [Full Text] [Related]  

  • 20. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
    Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
    J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.